-
American Journal of Clinical Dermatology 2002Clindamycin/benzoyl peroxide gel has demonstrated clinical efficacy in the treatment of acne vulgaris through both antibacterial and anti-inflammatory means. Benzoyl... (Review)
Review
UNLABELLED
Clindamycin/benzoyl peroxide gel has demonstrated clinical efficacy in the treatment of acne vulgaris through both antibacterial and anti-inflammatory means. Benzoyl peroxide may exert its antibacterial activity by the interaction of oxidized intermediates with elements of bacterial cells. Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunits causing inhibition of peptide-bond formation. Benzoyl peroxide decreases inflammatory damage by inhibiting the release of reactive oxygen species from polymorphonuclear leukocytes (PMNs) through the killing of PMNs. Clindamycin suppresses the complement-derived chemotaxis of polymorphonuclear leukocytes in vitro, thereby reducing the potential for inflammation. Several well designed clinical trials have demonstrated that twice-daily application of clindamycin 1%/benzoyl peroxide 5% gel for 10 to 16 weeks was more effective in reducing the number of inflammatory lesions than benzoyl peroxide 5%, clindamycin 1% or vehicle in patients with mild to moderately severe acne. Two studies also showed clindamycin/benzoyl peroxide to be more effective than benzoyl peroxide, clindamycin or vehicle in reducing total lesions, and one study showed clindamycin/benzoyl peroxide to be significantly more efficacious than clindamycin or vehicle in reducing the number of noninflammatory lesions. Moreover, in two trials, physician-rated mean global improvement scores, as well as patient-rated scores in one of those trials, were significantly greater in the clindamycin/benzoyl peroxide group than in the benzoyl peroxide, clindamycin or vehicle groups. In another study, clindamycin/benzoyl peroxide was as efficacious as benzoyl peroxide/erythromycin in the reduction of inflammatory and noninflammatory lesions and in raising mean global improvement scores, but was significantly more effective than benzoyl peroxide in the reduction of inflammatory lesions and in increasing both physician- and patient-assessed global improvement scores. Clindamycin/benzoyl peroxide gel applied twice daily was well tolerated in clinical trials in patients with acne, and has a tolerability profile similar to that of benzoyl peroxide alone. The most common adverse events were dry skin, peeling, erythema and rash; however, adverse event-caused treatment discontinuation rates for patients using clindamycin/benzoyl peroxide were low, ranging from 0 to 0.8%.
CONCLUSIONS
Clindamycin/benzoyl peroxide gel has demonstrated efficacy and good overall tolerability in several well designed clinical studies in the topical treatment of patients with mild to moderately severe acne vulgaris. Clindamycin/benzoyl peroxide was more effective than benzoyl peroxide, clindamycin or vehicle, and similar in efficacy to benzoyl peroxide/erythromycin in the reduction of inflammatory lesions and in raising physician- and patient-assessed mean global improvement scores. It may be useful in treating patients with acne caused by resistant strains of Propionibacterium acnes. Clindamycin/benzoyl peroxide gel is an effective topical agent in the treatment of patients with mild to moderately severe acne. It is a suitable alternative for patients who are currently using topical antibacterials either alone or in conjunction with other topical anti-acne agents or systemic antibacterials.
Topics: Acne Vulgaris; Administration, Cutaneous; Anti-Bacterial Agents; Benzoyl Peroxide; Clindamycin; Drug Combinations; Gels; Humans; Randomized Controlled Trials as Topic
PubMed: 12069641
DOI: 10.2165/00128071-200203050-00007 -
Expert Opinion on Pharmacotherapy Oct 2009Owing to the use of topical and systemic antibiotics for acne vulgaris, the incidence of antibiotic-resistant Propionibacterium acnes is increasing worldwide. Topical... (Review)
Review
BACKGROUND
Owing to the use of topical and systemic antibiotics for acne vulgaris, the incidence of antibiotic-resistant Propionibacterium acnes is increasing worldwide. Topical benzoyl peroxide (BPO) is an alternative to antibiotics in the treatment of acne vulgaris.
OBJECTIVE
This review describes and evaluates recent clinical literature regarding the efficacy and tolerability of BPO.
METHODS
A PubMed literature search was conducted using the keywords benzoyl peroxide, acne, and combination therapy.
RESULTS
BPO is equally effective at concentrations of 2.5, 5.0 and 10%. However, a concentration-dependent irritant dermatitis can occur with higher concentrations. The efficacy of BPO can be enhanced when used in combination with topical retinoids, antibiotics and tertiary amines. BPO-containing combinations do not induce bacterial resistance and are important first-line treatments for mild to moderate acne vulgaris.
Topics: Acne Vulgaris; Administration, Cutaneous; Anti-Bacterial Agents; Benzoyl Peroxide; Clinical Trials as Topic; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Propionibacterium acnes
PubMed: 19761357
DOI: 10.1517/14656560903277228 -
Environmental Health Perspectives Mar 2024
Topics: Benzene; Benzoyl Peroxide
PubMed: 38483533
DOI: 10.1289/EHP13984 -
Journal of Shoulder and Elbow Surgery Jan 2023Cutibacterium acnes (C acnes) colonization can have a significant impact on patients undergoing both arthroscopic and open shoulder surgery with regard to postoperative... (Review)
Review
BACKGROUND
Cutibacterium acnes (C acnes) colonization can have a significant impact on patients undergoing both arthroscopic and open shoulder surgery with regard to postoperative infection. Its resistance to standard preoperative skin preparations and prophylactic antibiotics has led to a need for a more targeted therapy. Topical benzoyl peroxide (BPO) has been used by dermatologists in the treatment for acnes due to its bactericidal and penetrative effects through the dermal layer. The aim of this systematic review is to review the effectiveness of topical BPO preoperatively in shoulder surgery in reducing C acnes colonization and postoperative infection.
METHODS
A review of the online databases Medline and Embase was conducted on December 15, 2021, according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The review was registered prospectively in the PROSPERO database. Clinical studies reporting superficial and deep sample microbiology and postoperative complications were included. The studies were appraised using the revised Cochrane Risk of Bias 2 (ROB 2) tool for randomized studies and the Methodological Index for Non-Randomized Studies (MINORS) tool.
RESULTS
The search strategy identified 10 studies for inclusion (6 randomized control trials, 2 prospective cohort studies, and 2 case series), including a total of 482 patients. Seven studies were comparable, testing BPO against alternative standard skin preparations. Of the 10 studies, 7 showed a decrease in the load of C acnes on the skin and/or deep tissues, of which 6 demonstrated statistical significance. Men were shown to have a statistically significant increase in the colonization rate of C acnes. Scheer et al (2021) demonstrated 4500 colony-forming units/mL in males and 900 colony-forming units/mL in females. In studies where the number of BPO applications was higher, BPO appeared more effective. Dizay et al demonstrated C acnes elimination in 78.9% with more than 1 application compared with 66.7% if only applied once. Three studies looked at the effectiveness of BPO during the operative timeline with 1 demonstrating its statistically significant effectiveness at reducing colonization 2 hours into the operation (P = .048).
CONCLUSION
BPO is effective as a topical treatment at reducing C acnes colonization before shoulder surgery. However, the relationship between duration of treatment, frequency of application, and gender requires further research.
Topics: Male; Female; Humans; Benzoyl Peroxide; Shoulder; Prospective Studies; Shoulder Joint; Propionibacterium acnes; Skin
PubMed: 36067940
DOI: 10.1016/j.jse.2022.07.019 -
The Journal of Dermatological Treatment Aug 2013Benzoyl peroxide (BPO) is widely utilized in acne treatment as an alternative to antibiotics against which Propionibacterium acnes becomes more resistant. (Review)
Review
BACKGROUND
Benzoyl peroxide (BPO) is widely utilized in acne treatment as an alternative to antibiotics against which Propionibacterium acnes becomes more resistant.
OBJECTIVE
This overview examines BPO dose justification.
METHODS
PubMed, Embase® and Science Citation Index searches were conducted using the keywords "benzoyl peroxide" and "acne vulgaris".
RESULTS
Limited experimental data are available. However, there appears no significant difference in the efficacy of concentrations from 2.5% to 10%.
DISCUSSION
The extent of free fatty acids and the percutaneous penetration of BPO may not play a critical role in acne vulgaris.
Topics: Acne Vulgaris; Administration, Topical; Benzoyl Peroxide; Dermatologic Agents; Humans; Propionibacterium acnes; Skin; Treatment Outcome
PubMed: 22103743
DOI: 10.3109/09546634.2011.641937 -
Skinmed 2023Epsolay cream is a novel topical treatment that utilizes microencapsulated benzoyl peroxide to treat moderate to severe papulopustular rosacea. It is effective at...
Epsolay cream is a novel topical treatment that utilizes microencapsulated benzoyl peroxide to treat moderate to severe papulopustular rosacea. It is effective at decreasing, and for some patients clearing, the papules, pustules, and telangiectasias associated with rosacea. It is well-tolerated with minimal adverse effects and has demonstrated efficacy comparable to other topical agents that are used for the condition.
Topics: Humans; Metronidazole; Rosacea; Benzoyl Peroxide; Administration, Topical; Emollients; Dermatologic Agents; Treatment Outcome
PubMed: 37158351
DOI: No ID Found -
Journal of the American Academy of... Aug 2021
Comparative Study
Topics: Benzoyl Peroxide; Clothing; Cotton Fiber; Gels; Staining and Labeling
PubMed: 29753055
DOI: 10.1016/j.jaad.2018.05.008 -
International Journal of Dermatology Jul 1991
Review
Topics: Allergens; Animals; Benzoyl Peroxide; Carcinogens; Humans
PubMed: 1769765
DOI: 10.1111/j.1365-4362.1991.tb04862.x -
The Medical Letter on Drugs and... Feb 2023
Topics: Humans; Benzoyl Peroxide; Rosacea; Metronidazole; Dermatologic Agents; Administration, Cutaneous
PubMed: 36757349
DOI: 10.58347/tml.2023.1669c -
American Journal of Clinical Dermatology Dec 2011Adapalene 0.1%/benzoyl peroxide 2.5% gel (Epiduo™, Tactuo™) is the only fixed-dose combination product available that combines a topical retinoid with benzoyl... (Comparative Study)
Comparative Study Review
Adapalene 0.1%/benzoyl peroxide 2.5% gel (Epiduo™, Tactuo™) is the only fixed-dose combination product available that combines a topical retinoid with benzoyl peroxide; it targets three of the four main pathophysiologic factors in acne. This article reviews the therapeutic efficacy and tolerability of topical adapalene 0.1%/benzoyl peroxide 2.5% gel in the treatment of patients aged ≥ 12 years with acne vulgaris, as well as summarizing its pharmacologic properties. In three 12-week trials in patients aged ≥ 12 years with moderate acne, success rates were significantly higher with adapalene 0.1%/benzoyl peroxide 2.5% gel than with adapalene 0.1% gel or benzoyl peroxide 2.5% gel alone, and combination therapy had an earlier onset of action. In addition, significantly greater reductions in total, inflammatory, and noninflammatory lesion counts were seen in patients receiving adapalene 0.1%/benzoyl peroxide 2.5% gel than in those receiving adapalene 0.1% gel or benzoyl peroxide 2.5% gel alone. Adapalene 0.1%/benzoyl peroxide 2.5% gel did not significantly differ from clindamycin 1%/benzoyl peroxide 5% gel in terms of the reduction in the inflammatory, noninflammatory, or total lesion counts in patients with mild to moderate acne, according to the results of a 12-week trial. Twelve-week studies showed that topical adapalene 0.1%/benzoyl peroxide 2.5% gel in combination with oral lymecycline was more effective than oral lymecycline alone in patients with moderate to severe acne, and topical adapalene 0.1%/benzoyl peroxide 2.5% gel in combination with oral doxycycline hyclate was more effective than oral doxycycline hyclate alone in patients with severe acne. In patients with severe acne who responded to 12 weeks' therapy with topical adapalene 0.1%/benzoyl peroxide 2.5% gel plus oral doxycycline hyclate or oral doxycycline hyclate alone, an additional 6 months' therapy with adapalene 0.1%/benzoyl peroxide 2.5% gel was more effective than vehicle gel at maintaining response, with further improvement seen in adapalene 0.1%/benzoyl peroxide 2.5% gel recipients. A noncomparative study also demonstrated the efficacy of 12 months' therapy with adapalene 0.1%/benzoyl peroxide 2.5% gel in patients with acne vulgaris. Topical adapalene 0.1%/benzoyl peroxide 2.5% gel was generally well tolerated in patients with acne. In 12-week trials, the most commonly occurring treatment-related adverse events included erythema, scaling, dryness, and stinging/burning; these dermatologic treatment-related adverse events were usually of mild to moderate severity, occurred early in the course of treatment, and resolved without residual effects. Topical adapalene 0.1%/benzoyl peroxide 2.5% gel was generally well tolerated in the longer term, with dry skin being the most commonly occurring treatment-related adverse event over 12 months of treatment. In conclusion, adapalene 0.1%/benzoyl peroxide 2.5% gel is a valuable agent for the first-line treatment of acne vulgaris.
Topics: Acne Vulgaris; Adapalene; Administration, Cutaneous; Adolescent; Benzoyl Peroxide; Child; Dermatologic Agents; Drug Combinations; Gels; Humans; Naphthalenes; Time Factors
PubMed: 21967116
DOI: 10.2165/11208170-000000000-00000